

# **Influenza C incidence and herd immunity in Lancaster, UK, in the winter of 2014-2015**

Kate V Atkinson<sup>1†</sup>, Lisa A Bishop<sup>1,2</sup>, Glenn Rhodes<sup>3</sup>, Nico Salez<sup>4</sup>, Neil R McEwan<sup>5</sup>, Matthew J Hegarty<sup>5</sup>, Julie Robey<sup>6</sup>, Nicola Harding<sup>6</sup>, Simon Wetherell<sup>6</sup>, Robert M Lauder<sup>1</sup>, Roger W Pickup<sup>1,3</sup>, Mark Wilkinson<sup>2</sup> & Derek Gatherer<sup>1\*</sup>

<sup>1</sup> Division of Biomedical & Life Sciences, Faculty of Health & Medicine, Lancaster University, Lancaster LA1 4YT, UK

<sup>2</sup>Royal Lancaster Infirmary, Ashton Road, Lancaster LA1 4RP, UK

<sup>3</sup>Centre for Ecology & Hydrology, Lancaster Environment Centre, Lancaster University, Lancaster LA1 4AP, UK

<sup>4</sup>UMR\_D 190, Emergence des Pathologies Virales, Aix-Marseille University, 27 Bd Jean Moulin, 13005 Marseille cedex 05, France

<sup>5</sup>Institute of Biological, Environmental & Rural Sciences, Aberystwyth University, Aberystwyth SY23 3DA, UK

<sup>6</sup>Queen Square Medical Practice, 2 Queen Square, Lancaster LA1 1RP, UK

<sup>†</sup> *Present address:* University College London Hospitals NHS Foundation Trust, London

<sup>\*</sup> *Contact for correspondence:* Derek Gatherer, email: [d.gatherer@lancaster.ac.uk](mailto:d.gatherer@lancaster.ac.uk), Tel: +44-1524-592900. Division of Biomedical & Life Sciences, Faculty of Health & Medicine, Lancaster University, Lancaster LA1 4YT, UK

*Running head:* Influenza C: antibodies and sequences

## 28 **Abstract**

29 Influenza C is not included in the annual seasonal influenza vaccine, and has historically  
30 been regarded as a minor respiratory pathogen. However, recent work has highlighted its  
31 potential role as a cause of pneumonia in infants. We performed nasopharyngeal or nasal  
32 swabbing and/or serum sampling ( $n=148$ ) in Lancaster, UK, over the winter of 2014-2015.  
33 Using enzyme-linked immunosorbent assay (ELISA), we estimated a seropositivity of 77%.  
34 By contrast, only 2 individuals, both asymptomatic adults, were influenza C-positive by  
35 polymerase chain reaction (PCR). Deep sequencing of nasopharyngeal samples produced  
36 partial sequences for 4 genome segments in one of these patients. Bayesian phylogenetic  
37 analysis demonstrated that the influenza C genome from this individual is evolutionarily  
38 distant to those sampled in recent years and represents a novel genome constellation,  
39 indicating that it may be a product of a decades-old reassortment event. Although we find  
40 no evidence that influenza C was a significant respiratory pathogen during the winter of  
41 2014-2015 in Lancaster, we confirm previous observations of seropositivity in the majority  
42 of the population. We calculate that this level of herd immunity would be sufficient to  
43 suppress epidemics of influenza C and restricts the virus to sporadic endemic spread. (194  
44 words)

## 45 **Key words**

46 herd immunity, flu, ELISA, RT-PCR, deep sequencing, respiratory pathogen

## 47 **Introduction**

### 48 *Clinical presentation*

49

50 Influenza C (family *Orthomyxoviridae*, genus *Influenzavirus C*, species *Influenza C virus*)  
51 produces malaise and coryza when administered to susceptible healthy adult volunteers,  
52 with fever in a minority of cases [Joosting et al., 1968]. Historically, influenza C has been  
53 regarded as the least serious of the three species of influenza infecting humans, and  
54 seasonal vaccination programmes have been confined to influenzas A and B. More recent

*Influenza C: antibodies and sequences*

55 studies in Finnish army recruits confirmed influenza C's production of a mild respiratory  
56 illness in healthy adults, with only occasional complications [Kauppila et al., 2013].

57

58 However, in a paediatric context, acute respiratory illness and/or pneumonia have been  
59 reported as a consequence of influenza C infection [Calvo et al., 2006; Matsuzaki et al.,  
60 2007; Matsuzaki et al., 2003; Moriuchi et al., 1991; Peng et al., 1996; Principi et al., 2012;  
61 Shimizu et al., 2015] especially in those under 2 years old [Matsuzaki et al., 2006], as well as  
62 vomiting, diarrhoea, acute otitis media [Laxdal et al., 1966], a high rate of hospitalization  
63 [Gouarin et al., 2008] and even acute encephalopathy [Takayanagi et al., 2009]. There is  
64 increased recognition that under-reporting of influenza C in children is a problem [Pabbaraju  
65 et al., 2013]. This growing awareness of the paediatric clinical importance of influenza C  
66 raises the issue of its inclusion in the annual seasonal influenza vaccine, or its position as a  
67 candidate for vaccine development specifically for infants.

68

69 *Epidemiology*

70

71 Nearly 40% of adult volunteers were susceptible to administered influenza C [Joosting et al.,  
72 1968]. The 60% who did not develop disease after experimental exposure is neatly  
73 consonant with observation of seropositivity levels of 59% in Spain [Manuguerra et al.,  
74 1994], 61% in France [Manuguerra et al., 1992] and 57% in Brazil [Motta et al., 2000], and  
75 suggests that seropositivity may possibly confer resistance. By contrast, other studies have  
76 suggested that antibodies against influenza C tend to be more universal: 100% in an isolated  
77 Philippine village [Nishimura et al., 1987] and in US adults and children [Hilleman et al.,  
78 1953], 90% in Czechoslovakia, 86% in the Soviet Union [Vasil'eva et al., 1985] and 70% in  
79 East Germany [Tumova et al., 1983]. Antibody titre levels among those classed as  
80 seropositive, varied widely. Some studies have also found age-structured variability: in  
81 California, seropositivity of 64% in children under 5 but 98% in adults [Dykes et al., 1980]; in  
82 Japan, 40-50% in early childhood to nearly 100% in adulthood [Kaji et al., 1983]; in  
83 Louisiana, 47% in children to 96% in younger adults, but then a decline to 18% in the over-  
84 65s [O'Callaghan et al., 1980]; in France, 46% seropositivity in children, 76% in younger  
85 adults, but only 44% in the over-50s [Manuguerra et al., 1992].

*Influenza C: antibodies and sequences*

86

87 Influenza C does not appear to be seasonal, based on contemporaneous two-year surveys of  
88 its occurrence in Bucharest and Japan from 1988-1990 [Ionita et al., 1992; Moriuchi et al.,  
89 1991]. Using this observation together with the seropositivity data, it is possible to propose  
90 several epidemiological scenarios. The first of these is that influenza C is essentially an  
91 endemic virus in human populations, with more or less lifelong immunity conferred by  
92 exposure but, in the absence of a vaccination programme, a sufficient supply of newborns  
93 and unexposed adults to provide a host population. The decline in seropositivity in later life,  
94 found in at least two studies [Manuguerra et al., 1992; O'Callaghan et al., 1980], potentially  
95 due to immunosenescence, would then provide the virus with opportunities to infect  
96 individuals for a second time. The second scenario is that the virus is only intermittently  
97 epidemic. The variation in seropositivity according to place, time and individual age is  
98 therefore a reflection of previous epidemic history in different locations. The third scenario  
99 is that the virus is endemic but antigenically variable over time. Seropositivity would  
100 therefore be an unreliable guide to the true immune status of any individual. Individuals  
101 may acquire immunity, but this will eventually disappear as its value is eroded by antigenic  
102 drift, for which there is some evidence in influenza C [Chakraverty, 1978].

103

104 *Phylogenetics and molecular evolution*

105

106 The rate of nucleotide substitution is lower in influenza C than in A and B [Buonagurio et al.,  
107 1986; Gatherer, 2010; Muraki et al., 1996; Yamashita et al., 1988]. Like the other influenza  
108 viruses, influenza C has a segmented RNA genome, and reassortment has been detected  
109 [Buonagurio et al., 1986; Gatherer, 2010; Matsuzaki et al., 2003; Moriuchi et al., 1991; Peng  
110 et al., 1994; Racaniello and Palese, 1979]. There is also evidence of positive selection for  
111 evasion of the host immune system at two residues in the receptor-binding domain of the  
112 haemagglutinin-esterase (HE) protein, but the overall ratio of non-synonymous to  
113 synonymous substitutions ( $\omega$ ) across the genome is low, individual proteins ranging  
114 from 0.05 to 0.13 [Gatherer, 2010]. The low levels of  $\omega$  indicate a virus that is well  
115 adapted to its host, but the presence of positive selection in the HE receptor-binding  
116 domain also indicates selective pressure from the host immune system. This provides a

*Influenza C: antibodies and sequences*

117 molecular explanation for the observed antigenic drift [Chakraverty, 1978] and some  
118 evidence against the scenario that humans are likely to acquire lifelong immunity. Influenza  
119 C would therefore resemble influenza A and B in that a new vaccine would be required  
120 every time the antigenic drift had reached a certain extent, potentially annually.

121

122 The issue of endemicity versus sporadic epidemics also remains unresolved. Only one  
123 candidate epidemic surge has been identified, in Japan in 2004 [Matsuzaki et al., 2007]. The  
124 existence of reassorted strains indicates that double infection with two or more strains  
125 cannot be very infrequent, implying that it ought to be possible to detect numerous (or at  
126 least >1) strains co-circulating both temporally and geographically, previously demonstrated  
127 in Japan [Matsuzaki et al., 2007]. Indeed, a continually shifting pattern of segment  
128 combinations, referred to as genome constellations [Gatherer, 2010], is observed when full  
129 genomes are studied, a phenomenon also seen in influenza B [Chen and Holmes, 2008].  
130 Eight genome constellations circulating in the 1990s differed from the genome  
131 constellations present in a set of reference genomes from the 1940s to the 1980s [Gatherer,  
132 2010].

133

## 134 **Methods**

### 135 *Patient recruitment*

136 Lancaster (54.05°N 2.80°W) is a small city with a population of 45,000 rising to 141,000  
137 when surrounding towns and villages are included. The permanent resident population is  
138 >95% white and 18% are over age 65. 3 cohorts of participants were approached: 1) staff  
139 and students at Lancaster University, 2) patients attending a general practitioner (GP)  
140 consultation, 3) patients attending hospital clinics. After informed consent was given,  
141 patients with coryza and/or other symptoms consistent with respiratory infection, were  
142 classified as the symptomatic group ( $n=71$ ) and the remainder as asymptomatic ( $n=77$ ).  
143 Nasopharyngeal (or nasal) swabbing, blood sampling, or both, were performed on the  
144 patients, according to consent. Sample collection was performed from November 2014 to  
145 May 2015.

*Influenza C: antibodies and sequences*

146

147 *Sample processing*

148 Nasopharyngeal swabs (MW951SENT, Medical Wire) were used to remove cells and mucus  
149 from the rear wall of the nasopharynx or nose (according to consent) of patients, and the  
150 tips then snapped off directly into Sigma Virocult® medium.

151

152 Blood was drawn from forearm veins into Beckton Dickinson Vacutainer® tubes containing  
153 clot activator or from a finger prick, according to consent, using Beckton Dickinson Serum  
154 Separator® tubes (SST™). Serum was separated at 1000-2000g for 10 minutes (for arm  
155 samples) or at 6000-15000g for 90s (for finger-prick samples) and then stored at -80°C.

156

157 RNA was extracted from the nasopharyngeal swabs using a MagMAX™ Viral RNA Isolation  
158 Kit (Ambion). The quality and quantity of RNA extracted from samples was assessed by  
159 spectrophotometry using the NanoDrop® 1000 Spectrophotometer V3.3.0 (Thermo Fisher  
160 Scientific). cDNA was prepared using a High-Capacity RNA-to-cDNA™ Kit (Applied  
161 Biosystems®, Life Technologies™) and a Veriti® Thermal Cycler (Applied Biosystems®, Life  
162 Technologies™). The samples were incubated at 37°C for 60 minutes, before stopping the  
163 reaction at 95°C for 5 minutes and then holding at 4°C. Once completed, the plates were  
164 stored at -20°C.

165

166 Polymerase chain reaction (PCR) was then performed using a 7500 FAST Real-Time PCR  
167 system (Applied Biosystems®, Life Technologies™) with thermo-cycling carried out as  
168 follows: one cycle of 95°C for 10 min and 45 cycles of 95°C for 15 s and 60°C for 1 min. PCR  
169 primers for influenza C were as used previously [Salez et al., 2014]. Samples judged positive  
170 after quantitative PCR were processed using the Illumina Nextera XT library kit and deep  
171 sequenced in 2x126bp format using an Illumina HiSeq2500 system.

172

*Influenza C: antibodies and sequences*

173 Enzyme-linked immunosorbent assay (ELISA) was performed on the serum samples using  
174 influenza C antigen as previously described [Salez et al., 2014] and goat anti-human HRP-  
175 conjugated secondary antibody (ab6858, Abcam®) with SureBlue™ TMB Microwell  
176 Peroxidase Substrate solution. Absorbance was measured at 450nm using a Wallac  
177 Victor2™ (Perkin Elmer) plate reader. Anti-influenza C IgG was quantified by calibration of  
178 the peroxidase reaction against a standard dilution series of IgG concentrations. The  
179 threshold for seropositivity was placed at 2 standard deviations above the mean level of the  
180 negative control serum.

181

182 *Genome segment sequence assembly*

183 Illumina reads were trimmed of adapters and other non-genomic elements using CutAdapt  
184 1.1 [Martin, 2011: <https://pypi.python.org/pypi/cutadapt>], fastq-mcf 0.11.3 [Aronesty,  
185 2013: <https://expressionanalysis.github.io/ea-utils>], and trim\_galore  
186 ([http://www.bioinformatics.babraham.ac.uk/projects/trim\\_galore/](http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)), within the  
187 Read\_cleaner pipeline (Gatherer, unpublished, see Supplementary Data Pack). Ethical  
188 approval required that no genetic material remain within the samples which could enable  
189 identification of patients. Therefore, human genome and transcriptome sequences were  
190 removed by iterative alignment onto the NCBI, Ensembl and UCSC human iGenomes  
191 ([http://support.illumina.com/sequencing/sequencing\\_software/igenome.html](http://support.illumina.com/sequencing/sequencing_software/igenome.html)), first using  
192 bowtie 1.1.1 [Langmead et al., 2009: <http://bowtie-bio.sourceforge.net/index.shtml>], then  
193 BWA 0.7.12-r1039 [Li and Durbin, 2010: <http://bio-bwa.sourceforge.net>] within the Valet  
194 pipeline (Gatherer, unpublished, see Supplementary Data Pack). Following each alignment,  
195 extraction of unaligned reads was achieved using samtools 0.1.19 [Li et al., 2009:  
196 <http://samtools.sourceforge.net/>] and the next alignment commenced. Bowtie, BWA and  
197 samtools were co-ordinated using the Vanator pipeline [Jarrett et al., 2013:  
198 <https://sourceforge.net/projects/vanator-cvr>]. The resulting trimmed and cleaned reads  
199 are available from the Sequence Read Archive (<https://www.ncbi.nlm.nih.gov/sra/>:  
200 BioSamples SAMN05954290 and SAMN05954291, Runs SRR4733498 and SRR4733494)

201

*Influenza C: antibodies and sequences*

202 Influenza C genome C/Victoria/2/2012 (Genbank ref. KM504282) was selected as a  
203 representative of recently circulating influenza C and alignment of cleaned reads carried out  
204 using bowtie within the Valet pipeline. Consensus sequences were constructed using  
205 samtools 0.1.19 (bcftools and vcfutils functions). C/Victoria/2/2012 was used to fill gaps in  
206 the consensi and the bowtie alignment repeated. This cycle was performed until a stable  
207 consensus was obtained for each genome segment. The same process was repeated using  
208 BWA and combined consensi obtained. Alignment of reads to the final consensi was  
209 examined with Tablet [Milne et al., 2013: <https://ics.hutton.ac.uk/tablet>]. Resulting  
210 assemblies of more than 200 bases were submitted to GenBank (references KY075640 -  
211 KY075642). The remaining smaller fragments, along with composite partial segments used  
212 in phylogenetic analysis, are available in the Supplementary Data Pack. The new strain of  
213 influenza C identified was designated C/Lancaster/1/2015.

214

215 *Phylogenetics and genome constellations*

216 Sequence alignments of composite partial segments with full influenza C genomes from  
217 GenBank, were performed using Muscle [Edgar, 2004] in MEGA [Kumar et al., 2008:  
218 <http://www.megasoftware.net>] and neighbour joining trees [Saitou and Nei, 1987]  
219 constructed. Clock-like behaviour in sequence evolution on those trees was checked using  
220 TempEst [Rambaut et al., 2016: <http://tree.bio.ed.ac.uk/software/tempest>]. Bayesian  
221 phylogenetic analysis was performed in BEAST v.1.8.3 [Drummond and Rambaut, 2007:  
222 <http://tree.bio.ed.ac.uk/software/beast/>]. A Tamura [1992] 3-parameter (T93+G)  
223 substitution model, coalescent constant size tree prior and relaxed lognormal clock were  
224 run for 100 million iterations in BEAST, as previously [Gatherer, 2010]. A burn-in of 25% of  
225 all trees was used to create the consensus tree. Genome constellations were determined by  
226 establishing the clade, as defined by Gatherer [2010], in which each genome segment was  
227 located.



*Influenza C: antibodies and sequences*

228

229 **Results**

230 *Participants*

231 Of the 148 participants, 69 were male and 79 female. 71 were symptomatic and 77  
232 asymptomatic. Distribution of male and female participants within symptomatic and  
233 asymptomatic groups was assessed by a 2x2 chi-square test and was not statistically  
234 significant. Except for a relative excess of age group 20-29 participants (mostly from the  
235 university), age approximated a normal distribution. The summary clinical presentation  
236 within the symptomatic group, graph of age distribution and details of the chi-square tests  
237 are available in the Supplementary Data Pack.

238

239 *Influenza C seropositivity*

240 Of the 148 participants, 129 consented to donate serum. Of these 99 were seropositive and  
241 30 negative, giving a figure of 77% seropositivity. Figure 1 shows the anti-influenza C IgG  
242 concentration by age. Gender differences in seropositivity were also nearly absent (male  
243 2.5mg/dl, female 2.3mg/dl) with no statistical significance on t-test, but symptomatic  
244 individuals had slightly more IgG (symptomatic 2.6mg/dl, asymptomatic 2.2mg/dl),  
245 significant on a t-test at  $p < 0.05$ . A Mann Whitney U-test was performed on the distribution  
246 of seropositive individuals between each age group, and was not statistically significant (see  
247 Supplementary Data Pack).

248

249 *Incidence of detectable virus*

250 Two participants out of 148 (1.4%) were detected as positive for influenza C using PCR. Both  
251 were asymptomatic. On deep sequencing (SRR4733498 and SRR4733494), only one patient  
252 showed sufficient levels of influenza C reads for genome assembly to be attempted

*Influenza C: antibodies and sequences*

253 (SRR4733498). If the other individual is a false positive by PCR, the population incidence  
254 may therefore be 0.7%. This figure is compromised by the fact that the sample is not  
255 randomly selected, but is deliberately enriched for symptomatic individuals (71/148, 48%).  
256 Since incidence is also often given as positive individuals per symptomatic case, and neither  
257 positive individual was symptomatic; on that strict formulation the incidence is 0%. In view  
258 of this, we can say little other than that influenza C incidence is low and probably accounted  
259 for <1% of coryza and other respiratory disease in Lancaster during the winter of 2014-2015.

260

261 *Genetic relationships of isolated influenza C genome segments*

262 Partial genome segment sequences were obtained from deep sequencing for segments 1, 5,  
263 6 and 7, encoding PB2, NP, M1/CM2 and NS1/NS2 respectively. Those greater than 200  
264 bases are deposited in GenBank, accession numbers KY075640 - KY075642 and the  
265 remainder are available in the Supplementary Data Pack. Insufficient reads were available  
266 to assemble the other segments. Although breadth of coverage across segments is low  
267 (ranging from 22% in segment 5 to 32% in segment 6), there is sufficient genetic information  
268 to assign each fragment to a clade as defined by Gatherer [2010], using Bayesian  
269 phylogenetics. Plotting of the root-to-tip genetic distance on a neighbour-joining tree using  
270 TempEst showed that molecular clocks apply best to segments 2 and 7 (PB2 and NS1/NS2),  
271 but that both segments 5 and 6 (NP and M1/CM2) have lower root-to-tip distances for  
272 C/Lancaster/1/2015 than expected. Figures 2 and 3 shows the TempEst plots for segments  
273 1 and 6 (PB2 and M1/CM2), giving examples of clock-like and non-clock-like behaviour,  
274 respectively. The TempEst plots for segments 5 and 7 (NP and NS1/NS2) are Supplementary  
275 Figures 3 and 4 respectively.

276

277 Clade memberships were determined by examination of Bayesian phylogenetic trees  
278 produced in BEAST, following the classificatory scheme of [Gatherer, 2010] and then  
279 annotated onto the neighbour-joining trees used for the molecular clock analysis. Figure 4  
280 shows the tree for segment 5 (encoding NP), demonstrating that C/Lancaster/1/2015  
281 belongs to the C/Miyagi/1/93 clade, and not to the C/Greece/79 and C/pig/Beijing/81 clades  
282 circulating in recent isolates. Figure 5 shows the tree for segment 7 (encoding NS1/NS2) has

*Influenza C: antibodies and sequences*

283 an even more distant relationship to recent genomes, being part of the C/Sapporo/71 clade  
284 last seen in 1979. The phylogenetic trees for PB2 and MP are given in Supplementary  
285 Figures 1 and 2, and further confirm the genetic distance between C/Lancaster/1/2015 and  
286 other recently sequenced genomes. Clade memberships are then synthesised to derive the  
287 relationship between C/Lancaster/1/2015 and defined genome constellations (Table 1).

288

## 289 **Discussion**

### 290 *Herd immunity to influenza C*

291 Our participant group were 77% seropositive to influenza C. This is slightly higher than the  
292 57-61% levels from studies in western Europe and Brazil [Manuguerra et al., 1992;  
293 Manuguerra et al., 1994; Motta et al., 2000], within the range of the 70-90% found in  
294 eastern Europe [Tumova et al., 1983; Vasil'eva et al., 1985] but still considerably short of  
295 those studies reporting universal seropositivity in the USA and east Asia [Hilleman et al.,  
296 1953; Nishimura et al., 1987]. As in previous studies, our antibody titre levels were widely  
297 variable among those classed as seropositive, and our choice of threshold is purely  
298 statistical. However, we also found no statistically significant age-structured or gender-  
299 structured variability in seropositivity (Figure 1). This is at variance with some previous  
300 studies in the USA, Japan and Europe [Dykes et al., 1980; Kaji et al., 1983; Manuguerra et al.,  
301 1992; O'Callaghan et al., 1980]. It should also be noted that many serological studies on  
302 influenza C are now some decades old and techniques have varied over the years, so  
303 individual studies are not necessarily directly comparable. We also cannot exclude the  
304 possibility of some cross-reactivity of our influenza C antigen with antibodies to other  
305 influenza viruses, but this is also an issue in all previous studies.

306

307 Whatever the source of the initial antigenic stimulus for the production of anti-influenza C  
308 IgG, such seropositivity may be equivalent to immunity to influenza C, even if of a  
309 temporary or partial nature, and this may have implications for the epidemiology of the  
310 virus. We are not aware of any study on the reproductive number ( $R_0$ ) of influenza C,  
311 although extensive studies have been performed for influenza A [reviewed by Biggerstaff et

*Influenza C: antibodies and sequences*

312 al., 2014]. If we assume that the  $R_0$  of 1.28 for seasonal influenza A, calculated by  
313 Biggerstaff et al. [2014] as a median of 47 published values, also applies to influenza C, then  
314 the herd immunity threshold (HET) – at which  $R_t$  would be reduced to 1, and an epidemic  
315 would be unsustainable – is:

316

$$317 \text{ HET} = (R_0 - 1) / R_0 = (1.28 - 1) / 1.28 = 0.5$$

318

319 This implies that 50% immunity in the population would be sufficient to suppress any  
320 epidemic outbreak of influenza C. Our level of 77% seropositivity may therefore explain  
321 why the influenza C virus was so difficult to detect in our participant group. We also note  
322 that it is not relevant to this calculation if our 77% partially represents cross-reactive  
323 antibodies against influenza A and B. Regardless of the virus type that initially produced the  
324 antibodies, their binding to influenza C antigen in ELISA suggests that they may be  
325 effectively protective *in vivo* and would contribute to herd immunity.

326

327 *Influenza C evolution*

328 Neither of the two participants who were identified as influenza C-positive by PCR  
329 generated sufficient deep sequencing reads for complete genomes to be assembled. Our  
330 deep sequencing of the nasopharyngeal swabs of both of our PCR-positive participants,  
331 produced much fuller genome sequence results for other RNA viruses apart from influenza  
332 C, as well as sequences from a range of bacterial species (Atkinson *et al* in preparation). We  
333 therefore do not think that the difficulty in detecting influenza C, or in generating complete  
334 genomes, is due to RNA degradation or other technical failure, but rather a true reflection of  
335 the rarity of the virus and a low viral titre in infected individuals.

336

337 In the individual with the 4 partial genome segment sequences, it is evident that  
338 C/Lancaster/1/2015 is a reassortant that does not fall into any of the genome constellations  
339 previously classified [Table 1 and Gatherer, 2010]. It contains a rare NS1/NS2 segment of  
340 the C/Sapporo/71 clade, related to sequences that were last observed in the late 1970s.  
341 Influenza C genomes sequenced since 2010 all have the C/Shizuoka/79 clade in the NS1/NS2

*Influenza C: antibodies and sequences*

342 segment (Figure 5). C/Lancaster/1/2015 also has a rare NP segment of the C/Miyagi/1/93  
343 clade, related to sequences that were last observed around 2000 (Figure 4) and typical of  
344 genome constellation 4a (Table 1). The other segments are within clades found more  
345 recently, although C/Lancaster/1/2015's position within these clades is never close to any of  
346 the recent genome sequences (Supplementary Figures 1 and 2). The exact position of  
347 C/Lancaster/1/2015 on each segment's phylogenetic tree is rarely well supported by  
348 Bayesian phylogenetics posterior probability density, but its location within each of the  
349 broader clades is well supported (see Supplementary Data Pack). We therefore conclude  
350 that its apparent reassortant nature is unlikely to be simply an artefact of partial sequence  
351 information.

352

353 Tentative reconstruction of the reassortment event may be attempted. Gatherer [2010]  
354 defines genome constellation 4a as consisting of C/Sapporo/71, C/Miyagi/1/93,  
355 C/Sapporo/71 and C/Shizuoka/79 in segments 1, 5, 6 and 7 respectively. The corresponding  
356 clades for C/Lancaster/1/2015 are C/Sapporo/71, C/Miyagi/1/93, C/Sapporo/71 and  
357 C/Sapporo/71 (Table 1), suggesting that a strain of constellation 4a reassorted with one  
358 containing a C/Sapporo/71-clade segment 7. Since no strain containing a segment 7 of this  
359 clade has been seen since the 1970s and constellation 4a was only seen in the 1990s, it  
360 seems likely that the reassortment event occurred in the 1990s. This would also explain the  
361 dissimilarity of C/Lancaster/1/2015 in all of its segments, to other recently sequenced  
362 strains. We are tempted to speculate that this reassortant occurred locally in Lancaster, but  
363 in the absence of any other British genomes since C/England/892/1983 [Matsuzaki et al.,  
364 2016], which is itself incomplete, it is impossible to come a conclusion.

365

366 If this scenario is common in small isolated populations, influenza C diversity in terms of  
367 shifting genome constellations may be even greater than suggested from the available  
368 genomes. Rare strains may persist at low levels in small urban/rural locations, such as  
369 Lancaster. Our detection rate, at 0%, 0.7% or 1.4% depending on whether both samples, or  
370 merely one sample, is scored as positive, or whether asymptomatic individuals are included,  
371 is broadly similar to the 0.2% (frequency per symptomatic individual) found in another

*Influenza C: antibodies and sequences*

372 recently sampled British population [Smith et al., 2016]. The M1/CM2 (Figure 3) and NP  
373 segments (Supplementary Figure 3) for C/Lancaster/1/2015 have lower root-to-tip distances  
374 than expected under the assumption of molecular clock-like evolution. When this method  
375 is used on database-derived sequences, it is often taken as indicative of incorrect dating.  
376 However, given that we know precisely when our samples were collected, it is more likely to  
377 reflect a genuinely slower rate of evolution in these samples. The M1/CM2 segment of  
378 C/Lancaster/1/2015 is positioned in the phylogenetic tree near segments from the 1980s  
379 (Supplementary Figure 1) and the NP segment near segments from the 1990s and 2000  
380 (Figure 4). This same phenomenon of slowed molecular clock, and aberrant positioning with  
381 the phylogenetic tree, has been seen in some strains of Zaire ebolavirus [Lam et al., 2015]  
382 and also in the 1977 “Russian Flu” H1N1 outbreak [Wertheim, 2010], and is thought to be a  
383 consequence of the virus entering a host population where the serial interval – the time  
384 between infection of one host and the next in a transmission chain – is reduced and the  
385 virus therefore spends longer in a non-replicative state. For ebolavirus, this is assumed to  
386 be a non-typical animal reservoir host, and for Russian Flu possibly a laboratory freezer.  
387 Neither of these options would seem to be possible for influenza C, so it may simply be a  
388 cumulative result of low transmission rates within relatively small populations slightly  
389 delaying the average serial interval, conditions which could apply in Lancaster.

390

391 *Implications for vaccination strategy*

392 We began this study with the premise that influenza C might be a candidate for inclusion in  
393 the seasonal influenza vaccine. Our results do not provide any support for the proposition  
394 that vaccination of adults is appropriate, a conclusion also reached by Smith et al. [2016].  
395 Although we recruited 71 symptomatic individuals with a range of cold/flu-like symptoms,  
396 none of these was influenza C-positive, and none of the respiratory disease burden in  
397 Lancaster during our study period can be attributed to influenza C.

398

399 There may still be a case for vaccination of children in the light of published reports of  
400 serious respiratory disease caused by influenza C in that age group. [Calvo et al., 2006;  
401 Gouarin et al., 2008; Laxdal et al., 1966; Matsuzaki et al., 2007; Matsuzaki et al., 2006;

*Influenza C: antibodies and sequences*

402 Matsuzaki et al., 2003; Moriuchi et al., 1991; Peng et al., 1996; Principi et al., 2012; Shimizu  
403 et al., 2015; Takayanagi et al., 2009]. We recruited 6 participants in the <9 years age group  
404 but none were consented to allow serum sampling. In the single participant in the 10-19  
405 year age group, anti-influenza C IgG levels were at <1 mg/dl and this individual is classified  
406 as seronegative (Figure 1). Whether the higher levels of anti-influenza C IgG found in our  
407 adults are as a consequence of a single exposure, or limited number of exposures, during  
408 childhood, or are maintained by recurrent possibly sub-clinical infections (as in our 2  
409 positive participants) in adulthood, remains a matter of debate. The apparent slowing of  
410 evolutionary rate in the M1/CM2 and NP segments of C/Lancaster/1/2015, if caused by  
411 reduced average serial interval due to reduced number of infections in small isolated  
412 populations, possibly suggests the former.

413

414 (Text 4082 words)

415

## 416 **Figure Legends**

417 **Table 1: Clade membership of segments of C/Lancaster/1/2015** based on Bayesian  
418 phylogenetic analysis and the prior clade and genome constellation classifications of  
419 Gatherer [2010]. The rightmost column lists those clades found in other segments  
420 sequenced from 2010 onwards. Segments 1 and 6 of C/Lancaster/1/2015 are outliers within  
421 clades found in other recent genomes, but segments 5 and 7 are not.

422 **Figure 1: Anti-influenza C IgG concentration** (mg/dl), plotted for each individual against age.  
423 Blue: >2 standard deviations above negative control; green: 1-2 standard deviations above  
424 negative control; red: <1 standard deviation above negative control.

425 **Figure 2: Root-to-tip distance in a neighbour joining tree for segment 1** (encoding PB2) of  
426 the influenza C genome. 100 full-length or near full-length genome segments (2365 bases)  
427 are used plus the 724 discontinuous bases of segment 1 derived from deep sequencing.  
428 C/Lancaster/1/2015 has a degree of divergence from the root consistent with molecular  
429 clock-like behaviour in its lineage.

*Influenza C: antibodies and sequences*

430 **Figure 3: Root-to-tip distance in a neighbour joining tree for segment 6** (encoding  
431 M1/CM2) segment of the influenza C genome. 86 full-length or near full-length genome  
432 segments (1180 bases) are used plus the 380 discontinuous bases of segment 6 derived  
433 from deep sequencing. C/Lancaster/1/2015 is less divergent from the root than it should  
434 be given its known sampling date, consistent with a perturbation of molecular clock-like  
435 behaviour in its lineage.

436 **Supplementary Figure 1: Neighbour joining tree rooted on C/Taylor/1233/1947 for**  
437 **segment 6** (M1/CM2), annotated with clades derived from Gatherer [2010] and confirmed  
438 by BEAST analysis (see Supplementary Data Pack), demonstrating the closer relationship of  
439 C/Lancaster/1/2015 (red) to M1/CM2 segments of the C/Sapporo/71 clade from the 1980s  
440 than to recent isolates. Scale: substitutions per site.

441 **Supplementary Figure 2: Neighbour joining tree rooted on C/Taylor/1233/1947 for**  
442 **segment 1** (PB2), annotated with clades derived from Gatherer [2010] and confirmed by  
443 BEAST analysis (see Supplementary Data Pack), demonstrating the closer relationship of  
444 C/Lancaster/1/2015 (red) to PB2 segments of the C/Sapporo/71 clade from the 1970s and  
445 1980s than to recent isolates. Scale: substitutions per site.

446 **Supplementary Figure 3: Root-to-tip distance in a neighbour joining tree for segment 5**  
447 (encoding NP) of the influenza C genome. 96 full-length or near full-length genome  
448 segments (1809 bases) are used plus the 397 discontinuous bases of segment 5 derived  
449 from deep sequencing. C/Lancaster/1/2015 is less divergent from the root than it should be  
450 given its known sampling date, consistent with a perturbation of molecular clock-like  
451 behaviour in its lineage.

452 **Supplementary Figure 4: Root-to-tip distance in a neighbour joining tree for segment 7**  
453 (encoding NS1/NS2) segment of the influenza C genome. 134 full-length or near full-length  
454 genome segments (935 bases) are used plus the 288 discontinuous bases of segment 7  
455 derived from deep sequencing. C/Lancaster/1/2015 has a degree of divergence from the  
456 root consistent with molecular clock-like behaviour in its lineage.

457

458 **Acknowledgments**



*Influenza C: antibodies and sequences*

459 KVA received a Service Increment from Teaching (SIFT) studentship from University  
460 Hospitals of Morecambe Bay (UHMB) National Health Service (NHS) Foundation Trust, UK  
461 and performed this work as part of the requirements for the degree of Master of Science  
462 (MSc). Rosetrees Trust, UK, provided additional funding for deep sequencing (grant M395).

463

## 464 **Ethics Statement**

465 Informed consent was obtained from adult volunteers and supported assent from juveniles  
466 with prior informed parental consent. Ethical approval was granted by the UK National  
467 Research Ethics Service (NRES), reference 14/LO/1634, Integrated Research Application  
468 System (IRAS) Project 147631. The project was registered with the National Institute of  
469 Health Research (NIHR), UK as part of the NIHR Clinical Research Network (UKCRN)  
470 Portfolio, ID 17799.

471

## 472 **Data Accessibility Statement**

473 The Supplementary Data Pack containing statistical analyses on volunteers and ELISAs, BAM  
474 files and reference genomes for genome assemblies, genome fragments too short for  
475 inclusion in GenBank, BEAST inputs and outputs, TempEst inputs and outputs and pipeline  
476 Perl scripts, are available from: [doi://10.17635/lancaster/researchdata/111](https://doi.org/10.17635/lancaster/researchdata/111)

477

## 478 **References**

- 479 Aronesty E. 2013. Comparison of sequencing utility programs. *The Open Bioinformatics Journal*  
480 7(1):DOI:10.2174/1875036201307010001.
- 481 Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. 2014. Estimates of the reproduction  
482 number for seasonal, pandemic, and zoonotic influenza: a systematic review of the  
483 literature. *BMC infectious diseases* 14:480.
- 484 Buonagurio DA, Nakada S, Fitch WM, Palese P. 1986. Epidemiology of influenza C virus in man:  
485 multiple evolutionary lineages and low rate of change. *Virology* 153(1):12-21.
- 486 Calvo C, Garcia-Garcia ML, Centeno M, Perez-Brena P, Casas I. 2006. Influenza C virus infection in  
487 children, Spain. *Emerging infectious diseases* 12(10):1621-1622.
- 488 Chakraverty P. 1978. Antigenic relationship between influenza C viruses. *Archives of virology*  
489 58(4):341-348.
- 490 Chen R, Holmes EC. 2008. The evolutionary dynamics of human influenza B virus. *J Mol Evol*  
491 66(6):655-663.

*Influenza C: antibodies and sequences*


- 492 Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. BMC  
493 evolutionary biology 7:214.
- 494 Dykes AC, Cherry JD, Nolan CE. 1980. A clinical, epidemiologic, serologic, and virologic study of  
495 influenza C virus infection. Archives of internal medicine 140(10):1295-1298.
- 496 Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput.  
497 Nucleic acids research 32(5):1792-1797.
- 498 Gatherer D. 2010. Tempo and mode in the molecular evolution of influenza C. PLoS currents  
499 2:RRN1199.
- 500 Gouarin S, Vabret A, Dina J, Petitjean J, Brouard J, Cuvillon-Nimal D, Freymuth F. 2008. Study of  
501 influenza C virus infection in France. J Med Virol 80(8):1441-1446.
- 502 Hilleman MR, Werner JH, Gauld RL. 1953. Influenza antibodies in the population of the USA; an  
503 epidemiological investigation. Bulletin of the World Health Organization 8(5-6):613-631.
- 504 Ionita E, Lupulescu E, Alexandrescu V, Matepiuc M, Tecu C. 1992. Seroepidemiological study of the  
505 circulation of influenza C virus in man. Roumanian archives of microbiology and immunology  
506 51(4):263-269.
- 507 Jarrett RF, Gallagher A, Gatherer D. 2013. Molecular methods of virus detection in lymphoma.  
508 Methods Mol Biol 971:277-293.
- 509 Joosting AC, Head B, Bynoe ML, Tyrrell DA. 1968. Production of common colds in human volunteers  
510 by influenza C virus. British medical journal 4(5624):153-154.
- 511 Kaji M, Hiromatsu Y, Kashiwagi S, Hayashi J, Oyama S, Katagiri S, Homma M. 1983. Distribution of  
512 antibodies to influenza C virus. The Kurume medical journal 30(3):121-123.
- 513 Kauppila J, Ronkko E, Juvonen R, Saukkoriipi A, Saikku P, Bloigu A, Vainio O, Ziegler T. 2013. Influenza  
514 C virus infection in military recruits-symptoms and clinical manifestation. J Med Virol.
- 515 Kumar S, Nei M, Dudley J, Tamura K. 2008. MEGA: a biologist-centric software for evolutionary  
516 analysis of DNA and protein sequences. Briefings in bioinformatics 9(4):299-306.
- 517 Lam TT, Zhu H, Chong YL, Holmes EC, Guan Y. 2015. Puzzling Origins of the Ebola Outbreak in the  
518 Democratic Republic of the Congo, 2014. J Virol 89(19):10130-10132.
- 519 Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short  
520 DNA sequences to the human genome. Genome biology 10(3):R25.
- 521 Laxdal OE, Blake RM, Cartmill T, Robertson HE. 1966. Etiology of acute otitis media in infants and  
522 children. Canadian Medical Association journal 94(4):159-163.
- 523 Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform.  
524 Bioinformatics 26(5):589-595.
- 525 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The  
526 Sequence Alignment/Map format and SAMtools. Bioinformatics 25(16):2078-2079.
- 527 Manuguerra JC, Hannoun C, Aymard M. 1992. Influenza C virus infection in France. The Journal of  
528 infection 24(1):91-99.
- 529 Manuguerra JC, Hannoun C, Saenz Mdel C, Villar E, Cabezas JA. 1994. Sero-epidemiological survey of  
530 influenza C virus infection in Spain. European journal of epidemiology 10(1):91-94.
- 531 Martin M. 2011. Cutadapt removes adapter sequences from high-throughput  
532 sequencing reads. EMBnetJournal 17(1):10-12 <http://dx.doi.org/10.14806/ej.14817.14801.14200>.
- 533 Matsuzaki Y, Abiko C, Mizuta K, Sugawara K, Takashita E, Muraki Y, Suzuki H, Mikawa M, Shimada S,  
534 Sato K, Kuzuya M, Takao S, Wakatsuki K, Itagaki T, Hongo S, Nishimura H. 2007. A nationwide  
535 epidemic of influenza C virus infection in Japan in 2004. Journal of clinical microbiology  
536 45(3):783-788.
- 537 Matsuzaki Y, Katsushima N, Nagai Y, Shoji M, Itagaki T, Sakamoto M, Kitaoka S, Mizuta K, Nishimura  
538 H. 2006. Clinical features of influenza C virus infection in children. The Journal of infectious  
539 diseases 193(9):1229-1235.
- 540 Matsuzaki Y, Mizuta K, Sugawara K, Tsuchiya E, Muraki Y, Hongo S, Suzuki H, Nishimura H. 2003.  
541 Frequent reassortment among influenza C viruses. J Virol 77(2):871-881.


*Influenza C: antibodies and sequences*


- 542 Matsuzaki Y, Sugawara K, Furuse Y, Shimotai Y, Hongo S, Oshitani H, Mizuta K, Nishimura H. 2016.  
543 Genetic Lineage and Reassortment of Influenza C Viruses Circulating between 1947 and  
544 2014. *J Virol* 90(18):8251-8265.
- 545 Milne I, Stephen G, Bayer M, Cock PJ, Pritchard L, Cardle L, Shaw PD, Marshall D. 2013. Using Tablet  
546 for visual exploration of second-generation sequencing data. *Briefings in bioinformatics*  
547 14(2):193-202.
- 548 Moriuchi H, Katsushima N, Nishimura H, Nakamura K, Numazaki Y. 1991. Community-acquired  
549 influenza C virus infection in children. *The Journal of pediatrics* 118(2):235-238.
- 550 Motta FC, Luiz MO, Couceiro JN. 2000. Serological analysis reveals circulation of influenza C viruses,  
551 Brazil. *Revista de saude publica* 34(2):204-205.
- 552 Muraki Y, Hongo S, Sugawara K, Kitame F, Nakamura K. 1996. Evolution of the haemagglutinin-  
553 esterase gene of influenza C virus. *J Gen Virol* 77 ( Pt 4):673-679.
- 554 Nishimura H, Sugawara K, Kitame F, Nakamura K, Sasaki H. 1987. Prevalence of the antibody to  
555 influenza C virus in a northern Luzon Highland Village, Philippines. *Microbiology and*  
556 *immunology* 31(11):1137-1143.
- 557 O'Callaghan RJ, Gohd RS, Labat DD. 1980. Human antibody to influenza C virus: its age-related  
558 distribution and distinction from receptor analogs. *Infection and immunity* 30(2):500-505.
- 559 Pabbaraju K, Wong S, Wong A, May-Hadford J, Tellier R, Fonseca K. 2013. Detection of influenza C  
560 virus by a real-time RT-PCR assay. *Influenza and other respiratory viruses* 7(6):954-960.
- 561 Peng G, Hongo S, Kimura H, Muraki Y, Sugawara K, Kitame F, Numazaki Y, Suzuki H, Nakamura K.  
562 1996. Frequent occurrence of genetic reassortment between influenza C virus strains in  
563 nature. *J Gen Virol* 77 ( Pt 7):1489-1492.
- 564 Peng G, Hongo S, Muraki Y, Sugawara K, Nishimura H, Kitame F, Nakamura K. 1994. Genetic  
565 Reassortment of Influenza-C Viruses in Man. *Journal of General Virology* 75:3619-3622.
- 566 Principi N, Scala A, Daleno C, Esposito S. 2012. Influenza C virus-associated community-acquired  
567 pneumonia in children. *Influenza and other respiratory viruses*.
- 568 Racaniello VR, Palese P. 1979. Isolation of influenza C virus recombinants. *J Virol* 32(3):1006-1014.
- 569 Rambaut A, Lam TT, Carvalho LM, Pybus OG. 2016. Exploring the temporal structure of  
570 heterochronous sequences using TempEst (formerly Path-O-Gen) *Virus Evolution* 2(1):DOI:  
571 10.1093/ve/vew1007
- 572 Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic  
573 trees. *Molecular biology and evolution* 4(4):406-425.
- 574 Salez N, Melade J, Pascalis H, Aherfi S, Dellagi K, Charrel RN, Carrat F, de Lamballerie X. 2014.  
575 Influenza C virus high seroprevalence rates observed in 3 different population groups. *The*  
576 *Journal of infection* 69(2):182-189.
- 577 Shimizu Y, Abiko C, Ikeda T, Mizuta K, Matsuzaki Y. 2015. Influenza C Virus and Human  
578 Metapneumovirus Infections in Hospitalized Children With Lower Respiratory Tract Illness.  
579 *The Pediatric infectious disease journal* 34(11):1273-1275.
- 580 Smith DB, Gaunt ER, Digard P, Templeton K, Simmonds P. 2016. Detection of influenza C virus but  
581 not influenza D virus in Scottish respiratory samples. *Journal of clinical virology : the official*  
582 *publication of the Pan American Society for Clinical Virology* 74:50-53.
- 583 Takayanagi M, Umehara N, Watanabe H, Kitamura T, Ohtake M, Nishimura H, Matsuzaki Y, Ichiyama  
584 T. 2009. Acute encephalopathy associated with influenza C virus infection. *The Pediatric*  
585 *infectious disease journal* 28(6):554.
- 586 Tamura K. 1992. The rate and pattern of nucleotide substitution in *Drosophila* mitochondrial DNA.  
587 *Molecular biology and evolution* 9(5):814-825.
- 588 Tumova B, Scharfenorth H, Adamczyk G. 1983. Incidence of influenza C virus in Czechoslovakia and  
589 German Democratic Republic. *Acta virologica* 27(6):502-510.
- 590 Vasil'eva VI, Zakstel'skaia L, Govorkova EA, Rusakova EV, Alekseenkova LI. 1985. [Immunostructure  
591 of the population to the influenza C virus]. *Voprosy virusologii* 30(6):661-664.


*Influenza C: antibodies and sequences*

- 592 Wertheim JO. 2010. The re-emergence of H1N1 influenza virus in 1977: a cautionary tale for  
593 estimating divergence times using biologically unrealistic sampling dates. PLoS one  
594 5(6):e11184.
- 595 Yamashita M, Krystal M, Fitch WM, Palese P. 1988. Influenza B virus evolution: co-circulating  
596 lineages and comparison of evolutionary pattern with those of influenza A and C viruses.  
597 Virology 163(1):112-122.
- 598
- 599










0.002





0.0020

<b>Genome segment (encoded protein)</b>	<b>Clade of segment in Lancaster consensus, as defined by Gatherer [2010]</b>	<b>Genome constellation in which that clade is present</b>	<b>Clade(s) of other post 2009 genomes</b>
1 (PB2)	C/Sapporo/71	All, except 5	C/Greece/79; C/Sapporo/71
5 (NP)	C/Miyagi/1/93	4a	C/pig/115/Beijing/81; C/Greece/79
6 (M1/CM2)	C/Sapporo/71	All, except 2 & 3	C/Sapporo/71
7 (NS1/NS2)	C/Sapporo/71	None: clade not seen since 1970s	C/Shizuoka/79

**Table 1: Clade membership of segments of C/Lancaster/1/2015** based on Bayesian phylogenetic analysis and the prior clade and genome constellation classifications of Gatherer [2010]. The rightmost column lists those clades found in other segments sequenced from 2010 onwards. Segments 1 and 6 of C/Lancaster/1/2015 are outliers within clades found in other recent genomes, but segments 5 and 7 are not.